These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 24476554)
21. Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study. Yi Z; Li H; Li M; Hu J; Cai Z; Liu Z; Zhang C; Cheng C; He Y; Chen J; Zu X; Wang R World J Urol; 2024 Oct; 42(1):581. PubMed ID: 39419868 [TBL] [Abstract][Full Text] [Related]
22. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer. Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807 [TBL] [Abstract][Full Text] [Related]
23. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832 [TBL] [Abstract][Full Text] [Related]
24. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis. Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455 [TBL] [Abstract][Full Text] [Related]
25. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932 [TBL] [Abstract][Full Text] [Related]
27. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group. Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185 [TBL] [Abstract][Full Text] [Related]
28. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505 [TBL] [Abstract][Full Text] [Related]
29. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379 [TBL] [Abstract][Full Text] [Related]
30. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845 [TBL] [Abstract][Full Text] [Related]
31. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060 [TBL] [Abstract][Full Text] [Related]
32. Risk of prostate carcinoma death in patients with lymph node metastasis. Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561 [TBL] [Abstract][Full Text] [Related]
33. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T; Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406 [TBL] [Abstract][Full Text] [Related]
34. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer. Linder BJ; Boorjian SA; Umbreit EC; Carlson RE; Rangel LJ; Bergstralh EJ; Karnes RJ Int J Urol; 2013 Aug; 20(8):798-805. PubMed ID: 23278850 [TBL] [Abstract][Full Text] [Related]
35. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. Mikel Hubanks J; Boorjian SA; Frank I; Gettman MT; Houston Thompson R; Rangel LJ; Bergstralh EJ; Jeffrey Karnes R Urol Oncol; 2014 Jan; 32(1):26.e1-7. PubMed ID: 23395235 [TBL] [Abstract][Full Text] [Related]
36. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? Bastide C; Rossi D; Lechevallier E; Bladou F; Barriol D; Bretheau D; Grisoni V; Mancini J; Giusiano S; Eghazarian C; Van Hove A BJU Int; 2012 Feb; 109(4):525-30; discussion 531-2. PubMed ID: 21851534 [TBL] [Abstract][Full Text] [Related]
37. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312 [TBL] [Abstract][Full Text] [Related]
38. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865 [TBL] [Abstract][Full Text] [Related]
39. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. Makarov DV; Humphreys EB; Mangold LA; Carducci MA; Partin AW; Eisenberger MA; Walsh PC; Trock BJ J Urol; 2008 Jan; 179(1):156-61; discussion 161-2. PubMed ID: 18001801 [TBL] [Abstract][Full Text] [Related]
40. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]